Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
about
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters CommitteeOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisNew steroids and new salicylates in inflammatory bowel disease: a critical appraisalLow dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapsesIntestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugsOn the action of 5-amino-salicylic acid and sulfapyridine on M. avium including subspecies paratuberculosis.Review article: balsalazide therapy in ulcerative colitis.Review article: monitoring for drug side-effects in inflammatory bowel disease.Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitisBalsalazide disodium for the treatment of ulcerative colitis.Mesalamine with MMX technology for the treatment of ulcerative colitis.Current and future therapies for inflammatory bowel disease.Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial.Balsalazide in treating colonic diseases.Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity.Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews.Current and emerging maintenance therapies for ulcerative colitis.Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis.Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study.Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.Which 5-ASA?A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis.Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study.Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.Self-reported adherence to medical treatment prior to and during pregnancy among women with ulcerative colitis.
P2860
Q22242348-32C75739-B32A-4784-8302-E79F03BF9985Q24185774-BB1ADE04-7E76-474F-BD80-131A194B10BAQ24198786-9917FB2F-17A9-4EA2-8C73-0DF5197E6C39Q28192793-1C1A3008-CB9D-497C-8403-BDFFCB9417F0Q28205383-80B417DD-3A75-4DC3-BF77-909BE374DFC7Q28360107-E0C1848E-8DA0-4DFE-BF99-67CC2A2AC1ABQ33287467-A2E223E5-E4AA-43D5-88F0-75069B6F62AEQ34374154-26D4A256-1E58-470F-8A27-2A3B6ED4A5ABQ34585315-7E6FEDFC-A1B5-4477-B36D-192981616480Q35625435-E28D55B1-08B7-4104-BB99-FF724AFF0066Q35629109-461F06BD-8D88-4991-B565-023ABB144E16Q36715466-AE986563-6596-4F13-A9C7-DEA19A38BA79Q36930800-97958368-4AAD-4354-93BC-BED8B5511ECBQ37101734-4C6C8305-8963-4493-AF79-0D520C0B2D1DQ37345858-3EEBEE6F-AC76-44AB-884A-029057CD0695Q37345925-4EE0B321-C6A1-41C1-BBC9-F23E70167932Q37346047-F488AD07-A507-4783-9A0B-7120B8985555Q37405555-F0DD8A5B-8AA6-4D0C-9E07-6C223C44F6A5Q37587217-2EC18CE3-8A4A-4861-BDF1-BF2DEC65528CQ37827164-535437E3-032D-4549-A2D0-6FF34C671C80Q37892884-8DFD8091-176E-4C07-9F81-5E906F5B62F7Q38118053-1C755197-A9A6-4F8A-852F-05A5835362CEQ38197719-F57F19F1-D2D4-4513-8A38-6FC101DC099EQ38288749-F093AC35-A7B3-4DBA-9947-A1E8F5795187Q39946903-7E3C4DD8-457F-42EC-9361-93035D3B43D5Q42627096-0C6A7763-991B-4F27-A693-2D48891FE7C1Q43788265-CF0CAE69-3E2B-4C63-A6B6-123E3CB50C96Q43886725-381F58CD-08D5-4045-92B7-699ECCF3B61FQ44048310-8453561B-B3FD-4D69-9650-B0163FB90CA9Q44255869-C8EBCEA1-E078-4CCD-A3E6-E5130FE628DAQ44255881-BB82A19A-B66F-4485-8D75-B4A0BB822703Q44761471-A8D5B4FB-B514-461A-9460-93EBC27B46D1Q45295209-20D030D0-BE44-49C3-A241-6F58880682BBQ45713741-10A6CA75-5847-415C-9765-5ED59DBC351CQ45713744-3FB0C754-B641-4C43-BC52-CD8E60B56EE5Q54604888-48E0DEAE-461C-4577-9E00-2C39CD8C31CC
P2860
Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Maintenance of remission of ul ...... hs. ABACUS Investigator group.
@en
Maintenance of remission of ul ...... hs. ABACUS Investigator group.
@nl
type
label
Maintenance of remission of ul ...... hs. ABACUS Investigator group.
@en
Maintenance of remission of ul ...... hs. ABACUS Investigator group.
@nl
prefLabel
Maintenance of remission of ul ...... hs. ABACUS Investigator group.
@en
Maintenance of remission of ul ...... hs. ABACUS Investigator group.
@nl
P2093
P1476
Maintenance of remission of ul ...... hs. ABACUS Investigator group.
@en
P2093
Holdsworth CD
Schofield KJ
Swarbrick ET
P304
P356
10.1046/J.1365-2036.1998.00427.X
P407
P577
1998-12-01T00:00:00Z